Abstract
Background
Subependymal giant cell astrocytoma develops in a small proportion of tuberous sclerosis patients. There are still several controversies on the early diagnosis of the tumor, treatment of hydrocephalus, and timing of operation, etc.
Methods
From September 1996 to April 2006, 17 patients were admitted in neurosurgical department of “Beijing Tiantan Hospital”. The authors analyzed medical records and followed up every case.
Results
There are 18 tumors out of 17 patients. One patient had double tumors. Sixteen patients except one underwent tumor resection 17 times. Fifteen tumors out of 17 were gross totally removed; two were partially removed. One patient died of brain infarction postoperatively. Three out of 13 patients with preoperative hydrocephalus still needed ventriculoperitoneal shunt after tumor resection. There was no recurrence after total resection.
Conclusion
Diagnosis of tumor should be made by clinical criteria. Serial follow-up is essential for a suspected perimonro lesion to find tumor growth earlier. When there is growth, tumor should be removed as soon as possible. Hydrocephalus will resolve in most cases after tumor resection, while external drainage is suitable for emergent cases. Transcallosal and transcortical approaches are both effective to resect the tumor. Tumor will not recur after total removal.
Similar content being viewed by others
References
Jansen FE, van Nieuwenhuizen O, van Huffelen AC (2004) Tuberous sclerosis complex and its founders. J Neurol Neurosurg Psychiatry 75:770
Altman NR, Purser RK, Post MJ (1988) Tuberous sclerosis: characteristics at CT and MR imaging. Radiology 167:527–532
Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19:232–243
Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461
Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457–1466
Curatolo P, Bombardieri R, Cerminara C (2006) Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neuro l19:119–123
de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O (2007) Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60:83–89
Dashti SR, Robinson S, Rodgers M, Cohen AR (2005) Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg 102(Suppl):322–325
Nagib MG, Haines SJ, Erickson DL, Mastri AR (1984) Tuberous sclerosis: a review for the neurosurgeon. Neurosurgery 14:93–98
Conzen M, Oppel F (1990) Tuberous sclerosis in neurosurgery. An analysis of 18 patients. Acta Neurochir (Wien) 106:106–109
Roach ES, DiMario FJ, Kandt RS, Northrup H (1999) Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14:401–407
Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM, Zimmerman RA, Brody BA (1992) MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 183:227–238
Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C (1999) Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66:370–375
Bonnin JM, Rubinstein LJ, Papasozomenos SC, Marangos PJ (1984) Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study. Acta Neuropathol 62:185–193
Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23:115–121
Turgut M, Akalan N, Ozgen T, Ruacan S, Erbengi A (1996) Subependymal giant cell astrocytoma associated with tuberous sclerosis: diagnostic and surgical characteristics of five cases with unusual features. Clin Neurol Neurosurg 98:217–221
Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66(8):792–796
Shepherd CW, Gomez MR (1991) Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study. Ann N Y Acad Sci 615:375–377
Prahlow JA, Teot LA, Lantz PE, Stanton CA (1995) Sudden death in epilepsy due to an isolated subependymal giant cell astrocytoma of the septum pellucidum. Am J Forensic Med Pathol 16:30–37
Fujiwara S, Takaki T, Hikita T, Nishio S (1989) Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? Childs Nerv Syst 5:43–44
Byard RW, Blumbergs PC, James RA (2003) Mechanisms of unexpected death in tuberous sclerosis. J Forensic Sci 48:172–176
Sinson G, Sutton LN, Yachnis AT, Duhaime AC, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20:233–239
Kumar R, Singh V (2004) Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev 27:274–280
Beems T, Grotenhuis JA (2001) Subependymal giant-cell astrocytoma in tuberous sclerosis: endoscopic images and the implications for therapy. Minim Invasive Neurosurg 44:58–60
Hyman MH, Whittemore VH (2000) National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665
Palmieri A, De Vecchio E, Pirolo R, Gardeur D, Ambrosio A (1982) The current potential of neuroradiology in the diagnosis of tuberous sclerosis. Ital J Neurol Sci 3:229–233
Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–56
Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosom Cancer 42:213–27
Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498
Koenig MK, Butler IJ, Northrup H (2008) Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23:1238–1239
Muncy J, Butler IJ, Koenig MK (2009) Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 24:477
Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B (2009) Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 41:3677–3682
Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476–479
Wong M (2010) Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 51:27–36
Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773–1778
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiang, T., Jia, G., Ma, Z. et al. The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 27, 55–62 (2011). https://doi.org/10.1007/s00381-010-1159-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-010-1159-1